AzTrials
AzTrials

Spinal Cord IschemiaNCT04941157

Prophylactic vs Therapeutic Cerebrospinal Fluid Drain Placement During Endovascular Thoracoabdominal Aortic Aneurysm Repair

A study testing Cerebrospinal Fluid Drain Placement in people with Spinal Cord Ischemia, run by University of Alabama at Birmingham at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a pilot study to be performed at the University of Alabama at Birmingham (UAB) and the University of Massachusetts to determine the feasibility and develop the processes for a future randomized controlled trial to evaluate the occurrence of spinal cord ischemia after endovascular thoracoabdominal aneurysm… Read more about this study

Who is it for?
Ages 18 to 100 yearsHealthy volunteers can take part
Conditions the study is for
Spinal Cord Ischemia
What is being tested?
Cerebrospinal Fluid Drain Placement
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
2 sitesUnited States
Study dates
1 Oct 2022to 1 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age ≥18
  • Undergoing high risk endovascular thoraco-abdominal aortic aneurysm repair, based on aortic coverage length:
  • 2a: Extent I, II, III TAAA 2b: Extent IV TAAA with >5cm coverage above the celiac artery

Who cannot join

  • Active prison incarceration
  • active pregnancy
  • moribund patients
  • ruptured aneurysm
  • coagulopathy precluding CSF drain placement
  • urgent or emergent aneurysm repairs

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Univeristy of Alabama at Birmingham Hospital

    Birmingham, Alabama, 35213

  • UMass Memorial Health Hospital

    Worcester, Massachusetts, 01655

Other trials in United States

About this study

Official title: United States Aortic Research Consortium (ARC) Pilot Study: Prophylactic vs Therapeutic Cerebrospinal Fluid Drain Placement During Endovascular Thoracoabdominal Aortic Aneurysm Repair

This is a pilot study to be performed at the University of Alabama at Birmingham (UAB) and the University of Massachusetts to determine the feasibility and develop the processes for a future randomized controlled trial to evaluate the occurrence of spinal cord ischemia after endovascular thoracoabdominal aneurysm repair using prophylactic cerebrospinal fluid drains versus no pre-emptive drain. The research question to be addressed is as follows: In the setting of a comprehensive spinal cord ischemia prevention protocol, do prophylactic CSF drains decrease the rate of spinal cord ischemia (SCI) in patients undergoing endovascular thoracoabdominal aneurysm repair?

Read the detailed description

Endovascular techniques have transformed the management of thoracoabdominal (extending from the chest into the abdomen) aneurysms, with reduced early complications and death rates compared to open aortic repair operations.

However, injury to the spinal cord from reduced blood flow, termed spinal cord ischemia (SCI), continues to be a potentially devastating complication of these operations. SCI occurs in 2% to 15% of patients undergoing Thoracic and Thoracoabdominal Endovascular Aneurysm Repair, depending on length of aortic coverage, among other risk factors for SCI1. Paralysis and paraplegia resulting from SCI can be lead to profound long-term disability, as well as increased short and medium-term mortality. Only 25% of patients with permanent paralysis survive to one year due to complications that develop from SCI2. Additionally, SCI has tremendous financial consequences at many levels for the patient and the healthcare system, given the increased length of hospital/rehabilitation stay and the increased use of healthcare resources required for a paralyzed patient.

The avoidance of SCI is therefore critically important. Given the impact that SCI has on quality of life and survival after endovascular repair, avoidance of this complication is critical to the clinical success of the operation.

A number of strategies are in use to reduce the risk of developing SCI. These include elevation of the mean arterial pressure (blood pressure) to increase blood flow to the spinal cord, maintenance of an appropriate minimum hemoglobin concentration to improve oxygenation, prophylactic cerebrospinal fluid (CSF) drainage, as well as a number of procedural manipulations that are performed to decrease the occurrence of SCI3. CSF drainage is thought to improve spinal cord perfusion pressure by lowering the intraspinous pressure and thus increase the spinal cord perfusion pressure, given that the spinal cord perfusion pressure is the difference between mean arterial blood pressure and intraspinous pressure. Although prophylactic CSF drainage is widely used and conceptually attractive, it remains controversial due to its own inherent risk of complications4.

Despite its widespread use, the clinical effectiveness of prophylactic CSF drainage has not been definitively established, and the placement of these drains has a number of potential complications, including life threatening intracranial (brain) bleeding or spinal cord injury due to epidural (ie around the spinal cord) bleeding. There have been three randomized clinical trials of CSF drainage in patients undergoing open thoracoabdominal aortic surgery repair that demonstrated clinical effectiveness of CSF pressure drainage5. While these trials have some bearing on endovascular treatment, the findings are not fully generalizable to endovascular repairs given the inherent differences in the procedures and patient populations. Furthermore, these trials were conducted in the 1990s/early 2000s, and many aspects of perioperative care have changed since then, again limiting the applicability of the findings.

SCI has a spectrum of outcomes after it occurs, and may improve immediately with rescue maneuvers, or can lead to permanent paralysis. CSF drains can be placed prophylactically or placed post-operatively only if SCI develops6, which is often referred to as selective CSF drain placement. Prophylactic CSF drains have not been demonstrated to definitively prevent nor mitigate the severity of SCI in endovascular thoracoabdominal aortic repair, and it is not known whether outcomes of prophylactic drains are superior to selective drains7. Thus, many patients treated with prophylactic drains are put at risk for complications of drain placement and may not benefit from placement of the drain. Further, the strategies mentioned above for avoidance of SCI in the setting of potential CSF drain complications have lowered the incidence of SCI to a point where there is equipoise of prophylactic CSF drains versus selective drains, placed postoperatively only if SCI develops.

Demonstrative of this equipoise, standard of care is considered to be either prophylactic OR selective drain usage, depending on the surgeon and institution. Given this clinical equipoise, our intention is to evaluate the incidence of and outcomes of SCI with a pre-emptive CSF strategy versus placement only if SCI develops.

This is a pilot study to be performed at the University of Alabama at Birmingham (UAB) and the University of Massachusetts (UMass) to determine the feasibility and develop the processes for a future randomized controlled trial to evaluate the occurrence of SCI after endovascular thoracoabdominal aneurysm repair using prophylactic cerebrospinal fluid drains versus no pre-emptive drain. The research question to be addressed is as follows: In the setting of a comprehensive SCI prevention protocol, do prophylactic CSF drains decrease the rate of SCI in patients undergoing endovascular thoracoabdominal aneurysm repair?

Being tested
Cerebrospinal Fluid Drain Placement
Medical subject headings
Spinal Cord Ischemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cerebrospinal Fluid Drain PlacementProcedure or surgery

    Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study

Study groups in NCT04941157
Study groupRoleWhat they receive
Prophylactic cerebrospinal fluid drain placementExperimentalPatients randomized to receive the experimental treatment will have a prophylactic cerebrospinal fluid drain placed prior to their endovascular aortic repair. All components of the endovascular aortic repair are standard of care treatments.
Receives: Procedure: Cerebrospinal Fluid Drain Placement
Selective cerebrospinal fluid drain placementNo interventionPatients randomized to the control arm of the study will not receive a prophylactic cerebrospinal fluid drain prior to their endovascular aortic repair. Patients will receive a CSF drain post-operative as needed to treat any symptoms of spinal cord ischemia. This arm of the study is current standard of care.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Spinal Cord Ischemia Onset

    The primary outcome of this study is the rate of post-operative spinal cord ischemia. Onset of spinal cord ischemia will be defined by any new lower extremity neurologic deficit not attributable to another cause. Details of lower extremity neurologic exam will be collected during physical exam. Motor weakness will be measured using the Muscle Power Scale.

    Measured: Baseline to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jun 2021
  2. Study start1 Oct 2022
  3. Primary completion1 May 2024
  4. Study completion1 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04941157
Sponsor's protocol ID
IRB-300006588
Status last verified
Jan 2025
First submitted
10 Jun 2021
Last updated
10 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be collected electronically from UAB powerchart and stored in an encrypted and secure REDCap database (advanced clinical software application for data warehousing and healthcare analytics related to clinical trials) maintained centrally by UAB. Access to data will be limited to remembers of the research team identified on this IRB proposal. All shared data will be deidentified and related to procedural details and clinical outcomes. Data will be shared with the research team at the University of Massachusetts.

Questions about this trial

What is this clinical trial studying?

A study testing Cerebrospinal Fluid Drain Placement in people with Spinal Cord Ischemia, run by University of Alabama at Birmingham at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Spinal Cord Ischemia Onset (time frame: Baseline to 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in